CN102805814B - Application of Qian mountain blood activating paste to preparation of medicines for preventing and treating atherosclerosis - Google Patents
Application of Qian mountain blood activating paste to preparation of medicines for preventing and treating atherosclerosis Download PDFInfo
- Publication number
- CN102805814B CN102805814B CN201210301707.7A CN201210301707A CN102805814B CN 102805814 B CN102805814 B CN 102805814B CN 201210301707 A CN201210301707 A CN 201210301707A CN 102805814 B CN102805814 B CN 102805814B
- Authority
- CN
- China
- Prior art keywords
- blood
- rhizoma
- radix
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses new application of Qian mountain blood activating paste to the preparation of medicines for atherosclerosis. The Qian mountain blood activating paste is stuck to the outside of a neck; and by clinical verification, an effect of preventing and treating carotid atherosclerosis is good. The medicine serving as an external preparation is convenient to use and has a using effect of external treatment for internal diseases in traditional Chinese medical science.
Description
Technical field
The invention belongs to medical technical field, exactly, relate to the application of numerous mountains blood-activating cream in preparation treatment atheromatosis medicine.
Background technology
Numerous mountains blood-activating cream is by Eupolyphaga Seu Steleophaga, Radix Et Rhizoma Rhei, Radix Notoginseng, Rhizoma Corydalis, Sanguis Draxonis, Radix Dipsaci, Cortex Phellodendri, Olibanum, Myrrha, catechu, Herba Asari, Rhizoma Homalomenae, Pseudobulbus cremastrae seu pleiones, Rhizoma Alismatis, Cornu Saigae Tataricae, the Radix Aucklandiae, Pseudobulbus Bletillae (Rhizoma Bletillae), the Radix Angelicae Dahuricae, Ramulus Cinnamomi, Rhizoma Et Radix Notopterygii 20 taste medicines form, record in Chinese patent medicine provincial standard WS-10415 (ZD-0415)-2002, by Beijing, accomplishing pharmaceutcal corporation, Ltd produces, authentication code is the accurate word Z20025596 of traditional Chinese medicines, there is blood circulation promoting and blood stasis dispelling, relaxing muscles and tendons and activating QI and blood in the collateral, the effect of reducing swelling and alleviating pain, for skin, arthroncus, pain, movable unfavorable and traumatic injury, waist, the diseases such as knee osteoarthritis.
Atherosclerosis (Atherosclerosis, AS) is a kind of common disease, often involves the significant points such as the heart, cerebrovascular and causes serious consequence, accounts for mortality first place, is called as " No.1 killer ".
Carotid arterial atherosclerosis is a part for GAS, has common pathologic basis and risk factor with coronary artery, cerebral atherosclerosis.Carotid atherosclerosis, be regarded as reflecting the window of GAS pathological changes, and the same with systemic atherosclerosis, the cause of disease of carotid arterial atherosclerosis and pathogenesis are not yet very clear, main risk factor derive from hyperlipidemia, hyperglycemia, hypertension, fat etc.
The Therapeutic Method of carotid arterial atherosclerosis doctor trained in Western medicine comprises Drug therapy and non-drug therapy.Non-drug therapy method comprises carotid endarterectomy (CEA), carotid stents angioplasty and photochemistry carotid artery plasty.The Carotid artery stenting of non-medicine with its safety, effectively, Wicresoft, indication widely feature gained recognition and be expected to replace CEA.
Carotid arterial atherosclerosis is the pathogenetic major reason of cerebrovascular.Sex, age, hypertension, smoking, obesity, hyperlipemia and diabetes etc. are all to accelerate the important risk factor of progression of atherosclerosis.In clinical treatment, although the surgical intervention of carotid artery stenosis and intervention are ripe day by day, postoperative higher restenosis becomes the focus that people pay close attention to day by day.A large amount of clinical trials show that multiple Western medicine has the effect for the treatment of and stable CAS speckle, but the untoward reaction that long-term taking Western medicine causes is also very important.
The globality of differentiation of tcm and treatment has good prospect.The traditional Chinese medical science, from the viewpoint of whole, is grasped its pathogenic characteristic, gives determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, can bring into play the advantage that Chinese medicine regulates body function comprehensively, thereby the intervention of multipath, too many levels, many target spots, clinical studies show, Chinese medicine prevention atheromatosis integral body demonstrates certain advantage.
Summary of the invention
The object of the present invention is to provide a kind of numerous mountains blood-activating cream to prevent and treat the particularly new purposes in carotid arterial atherosclerosis medicine of atherosclerosis in preparation.
Numerous mountains blood-activating cream has the function of blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, expelling wind and removing dampness, relaxing muscles and tendons and activating QI and blood in the collateral, dispersing swelling and dissipating binds, the main outer treatment that is applied to osteoarthritis clinically, but the inventor is in the favorite outer discovery of clinical practice, numerous mountains are lived to patch in cervical region, plaque progression in stoping carotid arterial atherosclerosis, softens, eliminates speckle and alleviate speckle inflammation tool having an unexpected effect.
With clinical trial data, further illustrate effect of the present invention below.
Clinical trial data
Case diagnosis standard:
Clinical typing:
I-II type: approach normal arterial wall thickness, there is no calcification;
III type: the intimal thickening of disperse or little speckle are without calcification;
IV-V-type: have lipid or downright bad core, by fibrous tissue around, may be with calcification;
VI type: complicated speckle, exists the breaking of surface, hemorrhage and thrombosis;
VII type: calcified plaque;
VIII type: there is no the fibrous plaque of lipid core, can have less calcification.
Western medicine diagnose standard: check that by colorful Doppler ultrasound diagnostic apparatus Carotid Intima-media Thickness (IMT) determines Mottling formation clinically.Normal IMT value should be less than 1.0 millimeters, and IMT is intimal thickening between 1.0 to 1.2 millimeters, between 1.2 to 1.4 millimeters, is Mottling formation, and IMT is greater than 1.4 millimeters for carotid artery stenosis.
Standards of Chinese Medical Syndrome Differentiation: the sick position that carotid artery atherosclerosis plaques forms is at blood vessels, and old complaint is at the heart, kidney.Primary disease belongs to the categories such as the traditional Chinese medical science " dizzy ", " card of fainting ".Its pathogenesis normal with blood deficiency stasis, press from both sides on expectorant and disturb, mechanism of qi is obstructed relevant.Symptom: patient can occur dizzy, nausea and vomiting, walking is unstable, limb tremor, or blurred vision, or eyes vibration, dysphonia.Tongue is dim, white and greasy fur or yellow greasy, and pulse sinks string, or stringy and rolling pulse is unable.Method for the treatment of: benefiting QI for activating blood circulation, clearing and dissipating phlegm-heat, temperature three-way meridian.
Case is included in and exclusion standard:
(1) include case standard in:
1. meet above-mentioned Western medicine diagnose standard person;
2. the person that meets Chinese medical discrimination;
3. the age is 40---and 75 years old.
In view of carotid atherosclerotic plaque is often sent out in mid-aged population, thus the age be set as 40-75 year.
(2) Excluded cases standard:
1. the age is person below 40 years old or more than 75 years old.
Gestation, prepare gestation or women breast-feeding their children.
Allergic constitution, have drug allergy history, skin ulceration person.
4. merge intentionally, the serious primary disease such as liver, kidney and hemopoietic system, and psychotic.
Four, method for the treatment of:
Choose clinical eligible patient and amount to 57 examples, be respectively III type sufferer 15 examples, patient's carotid artery has the intimal thickening of disperse or little speckle without calcification;
IV-V-type patient 20 examples, patient has lipid or downright bad core, by fibrous tissue around, may be with calcification;
, there is the breaking of surface, hemorrhage and thrombosis in VI type sufferer 10 people: patient artery is with complicated speckle;
, there is less calcification in VIII type patient 12 people: patient's carotid artery does not have the fibrous plaque of lipid core.
Medication: 1. give numerous mountains blood-activating cream, stick carotid artery affected part and HUATUOJIAJI acupoint (DAZHUI acupoint is to sacrum caudal vertebra).
Blank group: 13 people.
2. course for the treatment of: 15 days, change dressings once, take a day off, then stick for every three days.After three courses for the treatment of, check color ultrasound.
3. the original therapeutic scheme of patient is constant, and original life style and dietary habit do not change, 45 days check carotid artery color ultrasounds.
(2) curative effect index is selected
1. primary symptom situation of change:
(1) conscious clinical symptoms:
Dizziness, headache, hypomnesis, nausea and vomiting, walking is unstable, moving obstacle or blurred vision, or eyes vibration, dysphonia.Or deafness and tinnitus
(2) carotid artery color ultrasound examination:
Recovery from illness:: speckle disappears.Effective: speckle quantity and volume reduce.Effective: speckle quantity and volume are unchanged.Invalid: speckle quantity and volume increase.
Efficacy assessment standard
Carotid atherosclerotic plaque color ultrasound standards of grading:
(1) speckle character
Normal: inner membrance is coarse, rough, not yet form speckle 0 minute
Slight: soft speckle, during speckle is, low echo, outstanding to intracavity; 1 minute
Moderate: hard speckle, strong echo is outstanding to intracavity, can accompanying sound shadow 2 minutes
Severe: mixed stain, low, in, strong echo speckle, often accompanies hemorrhagely, infects. and 3 minutes
(2) speckle number (especially take soft speckle and flat speckle as main)
Normal: 0 speckle 0 minute
Slight: below 2, speckle is 1 minute
Moderate: 3 specklees 2 minutes
Severe: more than 4 speckle is 3 minutes
(3) carotid artery flow drag index (RI)
It is normal: no blood kinetics changes,
Drag index was without significant change 0 minute
Slight: blood flow index slightly increases by 1 minute
Moderate: blood flow index obviously increases by 2 minutes
Severe: index seriously increases by 3 minutes
(4) Carotic Intima-media Thinkness (IMT)
Normal: IMT value should be less than 1.0 millimeters 0 minute
Slight: IMT between 1.0 to 1.2 millimeters 1 minute
Between moderate: IMT1.2 to 1.4 millimeter 2 minutes
Severe: IMT be greater than 1.4 millimeters 3 minutes
(5) carotid artery stenosis calibration (according to area-method):
Normal: without narrow 0 minute
Slight: to be narrowly less than 30%; 1 minute
Moderate: narrow 30%～60% 2 minute
Severe: be narrowly greater than 60% 3 minutes
Eight, curative effect of disease is judged:
(1) curative effect determinate standard:
(1) clinical recovery: speckle is all eliminated, carotid artery is without narrow, transference cure, no blood kinetics changes
(2) effective: speckle is most of to be eliminated, and carotid artery stenosis obviously improves, and symptom obviously alleviates, and resistance of blood flow obviously improves
(3) effective: speckle is partly eliminated, and carotid artery stenosis slightly improves, symptom is improved, and resistance of blood flow makes moderate progress
(4) invalid: speckle is without obvious elimination, and carotid artery stenosis is not improved, and symptom is not improved, and resistance of blood flow is not improved
(2) main single index curative effect determinate standard
1. speckle character
(1) clinical recovery: speckle is eliminated
(2) effective: grading system reduces by 2 grades
(3) effective: grading system reduces by 1 grade
(4) invalid: grading system does not decline or increases the weight of
2. speckle number:
(1) clinical recovery: speckle is eliminated
(2) effective: grading system reduces by 2 grades
(3) effective: grading system reduces by 1 grade
(4) invalid: grading system does not decline or increases
3. carotid artery flow drag index (RI)
(1) clinical recovery: no blood kinetics changes, no blood resistance
(2) effective: grading system reduces by 2 grades
(3) effective: grading system reduces by 1 grade
(4) invalid: grading system does not decline or resistance increment
4, Carotic Intima-media Thinkness (IMT)
(1) clinical recovery: Carotic Intima-media Thinkness is within normal range
(2) effective: grading system reduces by 2 grades
(3) effective: grading system reduces by 1 grade
(4) invalid: grading system does not decline or thickness increases
5, carotid artery stenosis calibration (according to area-method):
(1) clinical recovery: internal diameter of carotid is within normal range
(2) effective: grading system reduces by 2 grades
(3) effective: grading system reduces by 1 grade
(4) invalid: grading system does not decline or narrowness increases
(3) traditional Chinese medical science time disease efficacy assessment standard:
(1) clinical recovery: tcm clinical practice symptom and sign disappears or substantially disappears,
(2) effective: tcm clinical practice symptom and sign obviously improves
(3) effective: tcm clinical practice symptom and sign all take a favorable turn
(4) invalid: tcm clinical practice symptom and sign is not improved, even aggravated consequence:
Table 1, numerous mountains blood-activating cream of the present invention treatment carotid arterial atherosclerosis effect
| Grouping | Number of cases | Clinical cure | Effective | Effectively | Invalid | Total effective rate |
| Treatment group | 57 | 17 | 21 | 9 | 10 | 82％ |
| Blank group | 13 | 1 | 2 | 0 | 8 | 23％ |
| P value | P＜0.01 | P＜0.01 | P＜0.01 | P＜0.01 |
Claims (2)
1. numerous mountains blood-activating cream is prevented and treated the application in atherosclerosis medicine in preparation, and described numerous mountains blood-activating cream is comprised of Eupolyphaga Seu Steleophaga, Radix Et Rhizoma Rhei, Radix Notoginseng, Rhizoma Corydalis, Sanguis Draxonis, Radix Dipsaci, Cortex Phellodendri, Olibanum, Myrrha, catechu, Herba Asari, Rhizoma Homalomenae, Pseudobulbus cremastrae seu pleiones, Rhizoma Alismatis, Cornu Saigae Tataricae, the Radix Aucklandiae, Pseudobulbus Bletillae (Rhizoma Bletillae), the Radix Angelicae Dahuricae, Ramulus Cinnamomi, Rhizoma Et Radix Notopterygii 20 taste medicines.
2. the application of numerous mountains blood-activating cream according to claim 1 on the moving atherosis medicine of preparation control, is characterized in that the application of numerous mountains blood-activating cream in preparation control carotid arterial atherosclerosis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210301707.7A CN102805814B (en) | 2012-08-23 | 2012-08-23 | Application of Qian mountain blood activating paste to preparation of medicines for preventing and treating atherosclerosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210301707.7A CN102805814B (en) | 2012-08-23 | 2012-08-23 | Application of Qian mountain blood activating paste to preparation of medicines for preventing and treating atherosclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102805814A CN102805814A (en) | 2012-12-05 |
| CN102805814B true CN102805814B (en) | 2014-02-12 |
Family
ID=47229798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210301707.7A Active CN102805814B (en) | 2012-08-23 | 2012-08-23 | Application of Qian mountain blood activating paste to preparation of medicines for preventing and treating atherosclerosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102805814B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102293891B (en) * | 2011-08-30 | 2014-11-12 | 时秀燕 | Chinese medicine for treating cardiovascular disease and preparation method thereof |
-
2012
- 2012-08-23 CN CN201210301707.7A patent/CN102805814B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102805814A (en) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103083609B (en) | Traditional Chinese medicine for treating cervical spondylosis, lumbar intervertebral disc herniation and ankylosing spondylitis | |
| CN103239520B (en) | Moslemic ointment for treating osteoarthritis and preparation method of moslemic ointment | |
| CN101569699A (en) | Pharmaceutical composition for treating prostatitis and preparation method thereof | |
| CN101396541B (en) | Traditional Chinese medicine for treating the cervical vertebra disease | |
| CN103191382A (en) | Medicine for treating Bi syndrome and preparation method thereof | |
| CN102600434B (en) | Compound mixture for curing cervical vertigo | |
| CN102805814B (en) | Application of Qian mountain blood activating paste to preparation of medicines for preventing and treating atherosclerosis | |
| CN103536885B (en) | A kind of Chinese medicine for the treatment of nephrasthenia tinnitus | |
| CN103989968A (en) | Oral traditional Chinese medicinal composition for treating cervical spinal stenosis | |
| CN105311210A (en) | Pharmaceutical composition for treating rheumatoid bone diseases | |
| CN109908217A (en) | It is a kind of for treating the Chinese medicine composition and application thereof of arterial thrombus obliterans | |
| CN114949165B (en) | Anti-depression traditional Chinese medicine composition and preparation method thereof | |
| CN103961655A (en) | Medicament for treating femoral head necrosis and preparation method thereof | |
| CN103520591B (en) | Chinese medicine for chronic urticaria | |
| CN103341015B (en) | Medicine for treating three-highs and preparation method thereof | |
| CN114767801B (en) | Traditional Chinese medicine composition for preventing and treating atherosclerosis cerebral infarction | |
| CN106853207B (en) | Traditional Chinese medicine composition for treating juvenile myopia and preparation method thereof | |
| CN105687321A (en) | Traditional Chinese medicine composition for treating rheumatism | |
| CN1088334C (en) | Safflower tea | |
| CN104491556B (en) | A kind of Chinese medicine composition for the treatment of caused by hepatic stagnation qi stagnation prostatic hyperplasia | |
| CN106267086A (en) | A kind of Chinese medicine preparation treating primary glaucoma | |
| CN104645244A (en) | Traditional Chinese medicine composition for treating atherosclerosis | |
| CN104435329A (en) | Traditional Chinese medicinal composition for treating high pressure symptom of calcaneus | |
| CN104225072A (en) | Traditional Chinese medicine for treating impotence | |
| CN104027741A (en) | Oral traditional Chinese medicine composition capable of treating female chondromalacia patellae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |